Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
A pickup in the initial public offering market would be a boon to Danaher.
Lynk
0
9
A worker uses a machine made by Pall Corp. during a demonstration of the clarification stage of the production of influenza vaccine during a tour at a Sanofi Pasteur vaccine production facility in Swiftwater, Pennsylvania.
Stephen Hilger | Bloomberg | Getty Images
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that.
